Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

NGLY1 Deficiency: early-phase trial registry

1 of 2 indexed NGLY1 Deficiency trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

NGLY1 Deficiency: 2 US clinical trials tracked, 1 recruiting.

NGLY1 Deficiency is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Eva Morava-Kozicz, running 1 of these trials.

Enrollment posture brief

Registry condition ngly1-deficiency

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%NGLY1 Deficiency (this)50%
Open-enrollment share among volume-matched conditions near NGLY1 Deficiency

NGLY1 Deficiency lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for NGLY1 Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. NGLY1 Deficiency is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Grace Science 1 trials

Named interventions

Most-linked intervention names on NGLY1 Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

GlcNAc-GlcN Drug
1 trials
GS-100 Genetic
1 trials
Placebo Other
1 trials

US sites by state

Facility locations filed on NGLY1 Deficiency trials. A trial with sites in several states counts in each.

Washington 1 trials
Texas 1 trials
Pennsylvania 1 trials
New York 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this NGLY1 Deficiency page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NGLY1 Deficiency condition card totals 2 registered trials; most-linked intervention GlcNAc-GlcN; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.